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Introduction
The most common symptoms seen in patients with 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) are fever, cough, asthenia, or dyspnea 
[1]. Thrombocytopenia and lymphopenia are the 
most frequent hematological abnormalities observed 
in patients with SARS-CoV-2 infection [2, 3]. The 
mechanisms by which thrombocytopenia occurs 
are not yet known. However, it was suggested that 
it could be related to the direct effect of the virus 
on hematopoiesis, cytokine storm, an increase of 
autoantibodies and immune complexes, and increased 
consumption by platelet activation, aggregation, and 
microthrombi formation [4]. We present three cases 
of thrombocytopenia after a acute, highly lethal 
pneumonia coronavirus disease 2019 (COVID-19).
Case 1
A 76-year-old male presented to the emergency 
room with epistaxis and petechiae in the lower limbs 
15 days after discharge of COVID-19. The patient had 
several pathologies: hypertension, dyslipidemia, ex-
smoker with chronic obstructive pulmonary disease 
(COPD), and carrier of an aortic prosthetic tube 
since 2008 anticoagulated with rivaroxaban, he was 
under treatment with methotrexate due to rheumatoid 
arthritis. In 2018, a nephroureterectomy was done due 
to a urothelial carcinoma and in complete remission 
since then. The patient was previously admitted for 
8 days due to bilateral pneumonia with a positive 
nasopharyngeal swab for SARS-CoV-2 RNA detected 
by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR). He was treated with 
hydroxychloroquine, azithromycin, lopinavir/ritonavir, 
ceftriaxone, and corticosteroids. Anticoagulated 
with low-molecular-weight heparin (LMWH) during 
admission. The patient always maintained a platelet 
count (PLT) of over 150,000/mm3.
When the patient presented with epistaxis and 
petechiae was admitted to the emergency room he 
had a blood pressure (BP) of 122/54 mmHg, heart 
rate of 89 bpm, and oxygen saturation of 95% while 
he was breathing ambient air. Urgent laboratory tests 
revealed a PLT of 16,000/mm3, hemoglobin (Hb) – 
15.6 g/dL, white blood cells (WBC) – 5.8 x 103/mm3, 
lymphocytes – 0.93 x 103/mm3. Prothrombin time 
(PT) – 13.4 s, activated partial thromboplastin time 
(aPTT) – 34.1 s, D dimer – 0.52 mg/ml. At that time, 
he continued with positive PCR for SARS-CoV-2 
in the nasopharyngeal swab. Peripheral blood 
smear showed isolated thrombocytopenia without 
morphological alterations. Direct and indirect Coombs 
tests conducted were negative. Anti-PF4-heparin 
antibodies test proved negative. Autoimmune workup 
revealed positive antinuclear antibodies (ANA) and 
negative DNA. Bone marrow aspiration didn´t show 
morphological cellular disorders, compatible with 
peripheral thrombocytopenia. Viral serology studies 
for human immunodeficiency virus (HIV) and hepatitis 
C virus (HCV) were negative. He had hepatitis B virus 
(HBV) passed (HBsAg negative, positive Ac. HBs, and 
Ac. HBc) with negative PCR for DNA-HBV. Suspecting 
that SARS-CoV-2 was a causal factor in immune 
thrombocytopenia, we suspended rivaroxaban and 
then gave treatment with immunoglobulins (IVIG) at 
a dose of 0.4 mg/kg/day for 5 days and corticosteroids 
at 1 mg/kg/day was started. PLT after the second 
dose of IVIG reached to 30,000/mm3. At this point, 
anticoagulation with enoxaparin 20 mg/day was 
reinitiated, which was gradually increased by adjusting 
the dose to platelet count. Four days after treatment, 
after reaching PLT – 68,000 mm3, anticoagulation 
was administrated at therapeutic doses. The patient 
showed good evolution, without bleeding, and four 
days after admission, he was discharged home with 
a plan to be followed up in 1 week for repeat laboratory 
tests. One week later he had PLT – 134,000/mm3 with 
a descending corticosteroids treatment.
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Case 2
A 30-year-old male presented an episode of spontaneous epistaxis 
with a PLT of 50,000/mm3 on the second day of admission due 
to COVID-19. The patient had a previous history of a cortico 
dependent chronic ITP since childhood. In July 2018, he began 
treatment with Eltrombopag without response. In January 2019, 
a splenectomy was made with a complete response since then. In 
his last analytical control, he had PLT – 299,000/mm3. He went to the 
emergency room on March 17, 2020, with fever and cough of four 
days of evolution. Upon arrival, he presented a BP – 141/85 mmHg, 
heart rate – 126 bpm, temperature – 38°C, and 98% saturation on 
room air. Laboratory test revealed Hb – 17 g/dL, PLT – 60,000/mm3, 
WBC – 12.77 x 103/mm3, lymphocytes – 1.24 x 103/mm3, 
coagulation: INR – 1.21, prothrombin activity – 74%, aPTT – 31.1 s, 
D dimer – 0.1 g/dL. The physical examination revealed no petechiae 
or bruising. An emergency chest radiograph showed bilateral 
bibasal infiltrates. The nasopharyngeal swab was positive for SARS-
CoV-2. The patient was admitted and treated with lopinavir/ritonavir, 
hydroxychloroquine, and ceftriaxone.
After six days, he deteriorated radiologically with increasing oxygen 
requirements, with PLT around 50,000–85,000/mm3. He received 
a high dose of corticosteroids and a single dose of tocilizumab. After 
24 h, he reached PLT – 340,000/mm3 and the clinical improvement 
was observed, with a progressive decrease in oxygen requirement. 
He was discharged after 10 days with PLT – 666,000/mm3 and 
without oxygen.
Case 3
A 38-year-old female patient, with no relevant medical 
history, was diagnosed with ITP from the age of 4. She was 
splenectomized in June 2017 for a lack of response to treatment 
with corticosteroids and romiplostim. In October 2019, she was 
diagnosed with complete thrombosis of the left jugular vein.  She 
was anticoagulated with acenocoumarol at the time of inclusion. 
A study of hereditary and acquired thrombophilia revealed 
heterozygous mutation of the prothrombin gene. In March 2020, 
she came to the emergency room due to bruising with minimal 
trauma and petechiae in legs without other associated symptoms 
since 3 weeks of evolution. Laboratory tests revealed PLT – 
11,000/mm3. Acenocoumarol was discontinued and treatment with 
Immunoglobulins 1 g/kg/day × 2 doses and prednisone 40 mg/day 
were started. Four days later, she was admitted to the emergency 
room because of respiratory worsening with fever and cough. A chest 
radiograph showed bilateral opacities in lower fields compatible 
with COVID-19. Blood tests revealed counts of lymphocytes – 
1.2 x 103/mm3, PLT – 372,000/mm3, and D dimer – 0.54 g/dL. 
Discharged from the emergency department after having been 
administered with levofloxacin and hydroxychloroquine for seven 
days, he was monitored closely by telephone follow-up and 
treatment. Anticoagulation was restarted with enoxaparin 1.5 mg/kg, 
and prednisone was decreased to 30 mg/24 h until suspension on 
April 30. The serological SARS-CoV-2 test showed negative IgM and 
positive IgG antibodies. Since then she has remained stable with PLT 
around 90,000/mm3.
Discussion
Our patients presented with mild-severe thrombocytopenia but no 
evidence of severe active bleeding. The response to immunoglobulins 
and corticosteroids treatment was rapid and satisfactory. The temporal 
sequence suggests that the cause of immune thrombocytopenia was 
related to SARS-CoV-2 [2]. However, there are not yet sufficient data 
that demonstrate the physiopathology of this phenomenon. Given 
the current pandemic, we suggest screening for SARS-CoV-2 in all 
patients with new-onset cytopenias.
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